Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q1 FY27

Symbiox Investment & Trading Co Q1 FY27 Results: Net Profit ₹0.1 Cr, Up 0.0% YoY

Symbiox Investment & Trading Co. Ltd reported revenue from operations of ₹0.3 Cr (-40.0% YoY) and net profit of ₹0.1 Cr (+0.0% YoY) for Q1 FY27.

Q1 FY27 at a glance · ₹ crore
MetricQ1 FY27Q4 FY26Q1 FY26
Revenue from operations0.30.80.5
Total income0.30.80.5
Profit before exceptional items & tax0.10.00.1
Profit before tax0.10.00.1
Net profit0.10.00.1
Operating margin33.3%0.0%20.0%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Net profit, year on year+0.00%
Revenue, year on year-40.00%
Source

BSE results filing, NSE: SYMBIOX. Figures extracted from the filing.

Read the filing ↗

Symbiox Investment & Trading Co. Ltd: key numbers

Share price
₹2.00
Market cap
₹6.26 Cr
Revenue (annual)
₹1.60 Cr
Net profit (annual)
₹0.15 Cr
P/E (TTM)
38.5×Sector 22.0×
Promoter holding
3.33%+0.00% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Symbiox Investment & Trading Co. Ltd

All →
15:01 IST BSE
Annual Report

Symbiox Investment & Trading Company Annual Report

Symbiox Investment & Trading Company Ltd submitted its 47th Annual Report for the financial year 2025-26. The report includes the notice for the upcoming Annual General Meeting.

12:20 IST BSE
Other Announcement

Symbiox Investment & Trading Co Other Announcement

Symbiox Investment & Trading Company Ltd has issued a circular to shareholders providing the web-link and access path for its FY 2025-26 Annual Report.

12:11 IST BSE
Annual General Meeting

Symbiox Investment & Trading Co Annual General Meeting

Symbiox Investment & Trading Company Ltd will hold its 47th Annual General Meeting on September 28, 2026. The agenda includes adopting FY26 financial statements and director re-appointment.